An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis
Latest Information Update: 12 May 2022
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 01 May 2022 Results (n=130) published in the Clinical Pharmacology in Drug Development
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.